New Developments in Biomedical Innovation

Digital Health in Health Assessment & Medical Diagnostics Global Startups Landscape 2.5Q 2024 is evolving rapidly, driven by AI-powered innovations across various medical fields. AI-Driven Diagnostics: AI is at the forefront of medical diagnostics. Startups like Aiberry (mental health) and Aidoc (cardiovascular health) are using AI to analyze data in real-time, improving early diagnosis and decision-making. These technologies offer non-invasive, faster, and more accurate assessments than traditional methods. Medical Imaging and Radiology: AI-powered imaging is a key area, with startups like Aidence (lung cancer screening) and Paige (digital pathology) leading the way in enhancing radiological diagnostics. These companies are pushing the boundaries of precision medicine, improving early detection and workflow efficiencies for radiologists and pathologists alike. Portable and Wearable Devices: Portable and wearable diagnostic tools are gaining prominence, exemplified by Butterfly Network, Inc. (handheld ultrasound) and Hyperfine, Inc. (portable MRI). These startups are making high-quality medical imaging more accessible, especially in underserved regions. Predictive and Personalized Medicine: Companies like Cardiosense (cardiovascular health) and Freenome (cancer detection) are leveraging multi-sensor devices and AI to predict disease onset, providing personalized treatment recommendations. This shift toward predictive healthcare is reshaping patient care, enabling more proactive intervention strategies. Voice and Speech Biomarkers: In mental health, companies like Sonde Health, Inc. and Kintsugi are innovating by using voice technology to detect signs of depression and anxiety, proving the versatility of AI in mental health diagnostics and offering real-time mental health assessments. Women’s Health: LEVY Health (endocrine disorders and fertility), Sonio (prenatal ultrasound), and Nevia bio (early disease detection) are advancing women’s health diagnostics, focusing on reproductive and prenatal health through AI-powered decision support platforms. Cross-Specialty Diagnostics: Startups such as Viz.ai and PathAI provide cross-specialty diagnostic tools, focusing on synchronizing care in fields like neurology and pathology. Viz.ai facilitates faster stroke care with its AI-driven platform, whereas PathAI uses AI to enhance diagnostic accuracy in pathology, especially in cancer diagnostics. Global startups in this space are attracting significant investments, with companies like Aidoc raising substantial funds to expand their platforms to more conditions and regions. Achieving CE marking and FDA clearances, as seen with companies like Ultromics, is essential for global expansion and validation. #DigitalHealth #Healthcare #Assessment #Medical #Diagnostics #AIinHealthcare 

Today, in (quasi-) new technologies: RNA delivery with cell membrane-coated nanoparticles The authors of this new article have taken a significant step forward in nucleic acid drug delivery, particularly for mRNA-based vaccines. Traditional lipid carriers face challenges such as premature release and immunogenicity. In this research, a novel system using chitosan methacrylate-tripolyphosphate (CMATPP) nanoparticles was presented, which can be coated with biological membranes to enhance delivery efficiency. Some interesting findings to be aware of: 1) Controlled release: by coating CMATPP nanoparticles with red blood cell (RBC) membranes, the researchers significantly reduced the initial burst release of siRNA, offering a more controlled and sustained release profile. 2) Biomimetic approach: the use of RBC membranes not only controls release but also preserves key proteins, potentially extending circulation time and reducing immune recognition, a crucial factor for drug delivery systems. 3) Versatility in coating: The authors expanded this concept to include extracellular vesicles and cell-derived nanovesicles, demonstrating the adaptability of their system. Using microfluidic devices and electroporation, they've created hybrid CDN-CMATPP nanoparticles, which retain specific cell markers, hinting at possibilities for personalized medicine. 4) Enhanced stability and performance? The CMATPP nanoparticles, when cross-linked, maintain stability in physiological conditions, and when coated, they exhibit properties like reduced immunogenicity and better payload retention, critical for siRNA delivery. The ability to use different cell sources for membrane coatings opens new avenues for targeted drug delivery, while the use of microfluidics in their fabrication process suggests scalability and the potential for high-throughput production, crucial for clinical applications. Full link to the article here: https://lnkd.in/ebCtnf5N #RNATherapeutics #DrugDelivery #BiomimeticNanoparticles #BiotechInnovation #PersonalizedMedicine

"Australian scientists have successfully developed a research system that uses 'biological artificial intelligence' to design and evolve molecules with new or improved functions directly in mammal cells. The researchers said this system provides a powerful new tool that will help scientists develop more specific and effective research tools or gene therapies. Named PROTEUS (PROTein Evolution Using Selection) the system harnesses 'directed evolution', a lab technique that mimics the natural power of evolution. However, rather than taking years or decades, this method accelerates cycles of evolution and natural selection, allowing them to create molecules with new functions in weeks. This could have a direct impact on finding new, more effective medicines. For example, this system can be applied to improve gene editing technology like CRISPR to improve its effectiveness." #bioai